Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Cowen from a "strong-buy" rating to a "hold" rating.
MIST Stock Falls 66% Following Complete Response Letter for Cardamyst [Yahoo! Finance]
Milestone Pharmaceuticals downgraded to Hold from Buy at TD Cowen [Yahoo! Finance]
Milestone Pharmaceuticals Inc. (NASDAQ: MIST) was downgraded by analysts at TD Securities from a "buy" rating to a "hold" rating.
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology